Advertisement

CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris

Published:February 22, 2018DOI:https://doi.org/10.1016/j.jaad.2018.02.034

      Background

      Heterozygous mutations in caspase recruitment domain family member 14 gene (CARD14) have been shown to be associated with psoriasis and familial pityriasis rubra pilaris (PRP). Many subjects with CARD14 mutations display features of both disorders, which can result in diagnostic uncertainty. In addition, these eruptions are often recalcitrant to conventional psoriasis therapies such as methotrexate, oral retinoids, and tumor necrosis factor-α inhibitors.

      Objective

      We sought to describe the clinical characteristics, family history, and response to therapy in subjects with papulosquamous eruptions due to mutations in CARD14.

      Methods

      Subjects were referred for genetic testing as part of a registry of subjects with inherited disorders of keratinization. DNA was isolated from blood or saliva, and multiplex targeted sequencing or whole exome sequencing was performed. Clinical histories of subjects with CARD14 mutations were reviewed.

      Results

      We identified 15 kindreds with CARD14-associated papulosquamous eruption (CAPE). Characteristic features of CAPE include early age of onset; prominent involvement of the cheeks, chin, and ears; family history of psoriasis or PRP; minimal response to conventional topical and systemic psoriasis therapies; and improvement with ustekinumab.

      Limitations

      Relatively small sample size.

      Conclusions

      Many subjects with CARD14 mutations display characteristics of both psoriasis and PRP. We propose the term CARD14-associated papulosquamous eruption to describe this spectrum of disease. Subjects with clinical features suggestive of CAPE should undergo CARD14 sequencing and may benefit from treatment with ustekinumab.

      Key words

      Abbreviations used:

      CAPE (CARD14-associated papulosquamous eruption), IL (interleukin), NF-κB (nuclear factor κ light-chain enhancer of activated B cells), PRP (pityriasis rubra pilari)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bertin J.
        • Wang L.
        • Guo Y.
        • et al.
        CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B.
        J Biol Chem. 2001; 276: 11877-11882
        • Jordan C.T.
        • Cao L.
        • Roberson E.D.
        • et al.
        Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis.
        Am J Hum Genet. 2012; 90: 796-808
        • Jordan C.T.
        • Cao L.
        • Roberson E.D.
        • et al.
        PSORS2 is due to mutations in CARD14.
        Am J Hum Genet. 2012; 90: 784-795
        • Fuchs-Telem D.
        • Sarig O.
        • van Steensel M.A.
        • et al.
        Familial pityriasis rubra pilaris is caused by mutations in CARD14.
        Am J Hum Genet. 2012; 91: 163-170
        • Boyden L.M.
        • Vincent N.G.
        • Zhou J.
        • et al.
        Mutations in KDSR cause recessive progressive symmetric erythrokeratoderma.
        Am J Hum Genet. 2017; 100: 978-984
        • Griffiths W.A.
        Pityriasis rubra pilaris.
        Clin Exp Dermatol. 1980; 5: 105-112
        • Gelfand J.M.
        • Gladman D.D.
        • Mease P.J.
        • et al.
        Epidemiology of psoriatic arthritis in the population of the United States.
        J Am Acad Dermatol. 2005; 53: 573
        • Shbeeb M.
        • Uramoto K.M.
        • Gibson L.E.
        • O'Fallon W.M.
        • Gabriel S.E.
        The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991.
        J Rheumatol. 2000; 27: 1247-1250
        • Zachariae H.
        • Zachariae R.
        • Blomqvist K.
        • et al.
        Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study.
        Acta Derm Venereol. 2002; 82: 108-113
        • Liu P.Y.
        • Prete P.E.
        Arthritis associated with pityriasis rubra pilaris.
        BMJ Case Rep. 2010; 2010https://doi.org/10.1136/bcr.12.2009.2565
        • Chan H.
        • Liu F.T.
        • Naguwa S.
        A review of pityriasis rubra pilaris and rheumatologic associations.
        Clin Dev Immunol. 2004; 11: 57-60
        • Eytan O.
        • Sarig O.
        • Sprecher E.
        • van Steensel M.A.
        Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14.
        Br J Dermatol. 2014; 171: 420-422
        • Inoue N.
        • Dainichi T.
        • Fujisawa A.
        • Nakano H.
        • Sawamura D.
        • Kabashima K.
        CARD14 Glu138 mutation in familial pityriasis rubra pilaris does not warrant differentiation from familial psoriasis.
        J Dermatol. 2016; 43: 187-189
        • Has C.
        • Schwieger-Briel A.
        • Schlipf N.
        • et al.
        Target-sequence capture and high throughput sequencing identify a de novo CARD14 mutation in an infant with erythrodermic pityriasis rubra pilaris.
        Acta Derm Venereol. 2016; 96: 989-990
        • Takeichi T.
        • Kobayashi A.
        • Ogawa E.
        • et al.
        Autosomal dominant familial generalized pustular psoriasis caused by a CARD14 mutation.
        Br J Dermatol. 2017; 177: e133-e135
        • Lwin S.M.
        • Hsu C.K.
        • Liu L.
        • Huang H.Y.
        • Levell N.J.
        • McGrath J.A.
        Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14.
        Br J Dermatol. 2017; ([Epub ahead of print])https://doi.org/10.1111/bjd.15462
        • Scudiero I.
        • Zotti T.
        • Ferravante A.
        • Vessichelli M.
        • Vito P.
        • Stilo R.
        Alternative splicing of CARMA2/CARD14 transcripts generates protein variants with differential effect on NF-kappaB activation and endoplasmic reticulum stress-induced cell death.
        J Cell Physiol. 2011; 226: 3121-3131
        • Papp K.A.
        • Langley R.G.
        • Lebwohl M.
        • et al.
        Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
        Lancet. 2008; 371: 1675-1684
        • Leonardi C.L.
        • Kimball A.B.
        • Papp K.A.
        • et al.
        Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
        Lancet. 2008; 371: 1665-1674
        • Lebwohl M.
        • Yeilding N.
        • Szapary P.
        • et al.
        Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.
        J Am Acad Dermatol. 2010; 63: 571-579
        • Di Stefani A.
        • Galluzzo M.
        • Talamonti M.
        • Chiricozzi A.
        • Costanzo A.
        • Chimenti S.
        Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris.
        J Dermatol Case Rep. 2013; 7: 5-9
        • Ruiz Villaverde R.
        • Sanchez Cano D.
        Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy.
        Eur J Dermatol. 2010; 20: 630-631
        • Wohlrab J.
        • Kreft B.
        Treatment of pityriasis rubra pilaris with ustekinumab.
        Br J Dermatol. 2010; 163: 655-656
        • Napolitano M.
        • Lembo L.
        • Fania L.
        • Abeni D.
        • Didona D.
        • Didona B.
        Ustekinumab treatment of pityriasis rubra pilaris: a report of five cases.
        J Dermatol. 2018; 45: 202-206
        • Chowdhary M.
        • Davila U.
        • Cohen D.J.
        Ustekinumab as an alternative treatment option for chronic pityriasis rubra pilaris.
        Case Rep Dermatol. 2015; 7: 46-50
        • Feldmeyer L.
        • Mylonas A.
        • Demaria O.
        • et al.
        Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris.
        JAMA Dermatol. 2017; 153: 304-308